Mazalvix

Mesalazine, the active ingredient in Mazalvix, is a 5-aminosalicylic acid (5-ASA) derivative presented as an oral formulation for oral use. It is employed to treat inflammatory bowel conditions such as ulcerative colitis and mild‑to‑moderate Crohn’s disease affecting the colon, helping to reduce intestinal inflammation.

GNH USA supplies Mazalvix as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mazalvix, a 5‑ASA drug, is used in the management of inflammatory bowel disease.

- Ulcerative colitis: reduces mucosal inflammation and promotes remission. - Crohn's disease (mild to moderate colonic involvement): controls disease activity and alleviates symptoms. - Maintenance therapy for ulcerative colitis: helps sustain remission after induction.

Mesalazine may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Nausea - Abdominal pain or cramping - Headache - Flatulence or bloating - Diarrhea - Rash or mild skin irritation

Serious or Rare Side Effects: - Severe allergic reaction (anaphylaxis, angioedema) - Blood in stool or marked gastrointestinal bleeding - Elevated liver enzymes or hepatitis - Pancreatitis - Acute kidney injury or interstitial nephritis - Myocarditis or pericarditis

Before initiating therapy, clinicians should consider several safety measures.

- Renal function monitoring: assess serum creatinine and eGFR regularly. - Hepatic function monitoring: check liver enzymes periodically. - Disease activity assessment: ensure active inflammation is present before use. - Hypersensitivity: avoid in patients with known allergy to mesalazine or related 5‑ASA compounds. - Concomitant anticoagulants: use caution as bleeding risk may increase. - Store at ambient temperature: keep in original packaging, protect from moisture and direct sunlight.

Mesalazine can interact with several medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Azathioprine: may increase risk of bone marrow suppression. - Warfarin: can potentiate anticoagulant effect and raise bleeding risk. - Methotrexate: potential additive toxicity to liver and bone marrow.

Moderate Interactions (Monitor Closely): - NSAIDs: may exacerbate gastrointestinal irritation. - Oral contraceptives: possible reduction in contraceptive efficacy. - Lithium: mesalazine may alter lithium serum levels. - Allopurinol: monitor for increased risk of hypersensitivity reactions.